Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Trial of Lumiracoxib (COX189) 100 mg o.d. in Patients With Primary Hip Osteoarthritis Using Celecoxib (200 mg o.d.) as a Positive Control

NCT00154219 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00154219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00154219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Trial of Lumiracoxib (COX189) 100 mg o.d. in Patients With Primary Hip Osteoarthritis Using Celecoxib (200 mg o.d.) as a Positive Control
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2004
Completion date
Not reported
Enrollment
1,200
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis, hip